Search
SRP-6004
go.drugbank.com/drugs/DB16998InvestigationalA recombinant AAVrh74 gene therapy expressing the dysferlin transgene under control of a muscle-specific promoter (rAAVrh74.MHCK7.DYSF.DV).
VY-HTT01
go.drugbank.com/drugs/DB16999InvestigationalVY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. … VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.
AT-GTX-502
go.drugbank.com/drugs/DB17001ExperimentalAT-GTX-502 is an experimental, one-time gene therapy that uses AAV9 to deliver a functional copy of CLN3.
MRK-003
go.drugbank.com/drugs/DB17015ExperimentalMRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]
MK-4541
go.drugbank.com/drugs/DB17016ExperimentalMK-4541 is a 4-azasteroid and a selective androgen receptor modulator (SARM). MK-4541 acts as a dual selective SARM and is both a potent androgen receptor antagonist and a 5α-reductase inhibitor.
AMZ002
go.drugbank.com/drugs/DB17017InvestigationalAMZ002 is a sterile injectable hormone developed as a purified synthetic polypeptide alternative to current FDA-approved epileptic seizure treatments.
Ellipticine
go.drugbank.com/drugs/DB17026ExperimentalEllipticine is a potent antineoplastic agent.[A252992]
GBR-12783
go.drugbank.com/drugs/DB17027ExperimentalA selective inhibitor of dopamine uptake.[A252997]
GSK-269962A
go.drugbank.com/drugs/DB17030ExperimentalGSK-269962A is a Rho kinase (ROCK) inhibitor with both ROCK1 and ROCK2 affinity.[A253012]
Homidium
go.drugbank.com/drugs/DB17031InvestigationalHomidium is a group II compound with trypanocidal effects.[A253017]
Categories: Compounds used in a research, industrial, or household setting